Ken Griffin Chroma Dex Corp. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Chroma Dex Corp. stock. As of the latest transaction made, Citadel Advisors LLC holds 26,600 shares of CDXC stock, worth $140,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,600

Previous 17,900 48.6%

Holding current value

$140,980

Previous $48,000 102.08%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.51 - $3.8 $24,221 - $36,670	-9,650 Reduced 96.97%	302 $1,000
Q2 2024 Aug 14, 2024	SELL	$2.44 - $4.32 $75,837 - $134,269	-31,081 Reduced 75.75%	9,952 $27,000
Q1 2024 May 15, 2024	SELL	$1.36 - $3.84 $188,580 - $532,462	-138,662 Reduced 77.17%	41,033 $142,000
Q4 2023 Feb 14, 2024	BUY	$1.28 - $1.6 $8,864 - $11,080	6,925 Added 4.01%	179,695 $256,000
Q3 2023 Nov 14, 2023	SELL	$1.36 - $1.77 $19,642 - $25,564	-14,443 Reduced 7.71%	172,770 $252,000
Q2 2023 Aug 14, 2023	SELL	$1.31 - $1.79 $29,840 - $40,774	-22,779 Reduced 10.85%	187,213 $293,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.19 $88,357 - $130,745	59,701 Added 39.72%	209,992 $321,000
Q4 2022 Feb 14, 2023	BUY	$1.25 - $1.94 $117,157 - $181,828	93,726 Added 165.7%	150,291 $252,000
Q3 2022 Nov 14, 2022	SELL	$1.19 - $2.06 $377,220 - $653,003	-316,992 Reduced 84.86%	56,565 $70,000
Q2 2022 Aug 15, 2022	BUY	$1.59 - $2.7 $420,520 - $714,090	264,478 Added 242.46%	373,557 $623,000
Q1 2022 May 16, 2022	SELL	$2.02 - $3.92 $77,050 - $149,524	-38,144 Reduced 25.91%	109,079 $268,000
Q4 2021 Feb 14, 2022	BUY	$3.74 - $6.7 $419,841 - $752,121	112,257 Added 321.05%	147,223 $550,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $10.41 $34,727 - $59,753	5,740 Added 19.64%	34,966 $219,000
Q2 2021 Aug 16, 2021	SELL	$6.66 - $10.92 $293,579 - $481,364	-44,081 Reduced 60.13%	29,226 $288,000
Q1 2021 May 17, 2021	BUY	$4.59 - $18.74 $336,479 - $1.37 Million	73,307 New	73,307 $685,000
Q3 2020 Nov 16, 2020	SELL	$4.01 - $5.56 $119,113 - $165,154	-29,704 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.0 - $5.52 $131,253 - $241,505	-43,751 Reduced 59.56%	29,704 $137,000
Q1 2020 May 15, 2020	BUY	$2.54 - $4.75 $133,108 - $248,923	52,405 Added 248.95%	73,455 $239,000
Q4 2018 Feb 14, 2019	SELL	$2.8 - $4.22 $65,200 - $98,266	-23,286 Reduced 52.52%	21,050 $72,000
Q3 2018 Nov 13, 2018	BUY	$3.5 - $4.91 $95,602 - $134,116	27,315 Added 160.48%	44,336 $0
Q2 2018 Aug 10, 2018	SELL	$3.22 - $4.43 $136,267 - $187,473	-42,319 Reduced 71.32%	17,021 $0
Q1 2018 May 11, 2018	BUY	$4.05 - $6.46 $240,327 - $383,336	59,340 New	59,340 $249,000

Others Institutions Holding CDXC

# of Institutions

Shares Held

17.2M

Call Options Held

66.7K

Put Options Held

8.2K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $362M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account